345 related articles for article (PubMed ID: 19632322)
1. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells.
Cirstoiu-Hapca A; Buchegger F; Bossy L; Kosinski M; Gurny R; Delie F
Eur J Pharm Sci; 2009 Oct; 38(3):230-7. PubMed ID: 19632322
[TBL] [Abstract][Full Text] [Related]
2. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
[TBL] [Abstract][Full Text] [Related]
3. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
[TBL] [Abstract][Full Text] [Related]
4. Biodegradable nanoparticles for direct or two-step tumor immunotargeting.
Nobs L; Buchegger F; Gurny R; Allémann E
Bioconjug Chem; 2006; 17(1):139-45. PubMed ID: 16417262
[TBL] [Abstract][Full Text] [Related]
5. Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles.
Debotton N; Parnes M; Kadouche J; Benita S
J Control Release; 2008 May; 127(3):219-30. PubMed ID: 18343522
[TBL] [Abstract][Full Text] [Related]
6. Anti-KDEL-coated nanoparticles: a promising tumor targeting approach for ovarian cancer?
Delie F; Ribaux P; Petignat P; Cohen M
Biochimie; 2012 Nov; 94(11):2391-7. PubMed ID: 22713763
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.
Mattu C; Pabari RM; Boffito M; Sartori S; Ciardelli G; Ramtoola Z
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):463-72. PubMed ID: 23916461
[TBL] [Abstract][Full Text] [Related]
8. A quantitative evaluation of the molecular binding affinity between a monoclonal antibody conjugated to a nanoparticle and an antigen by surface plasmon resonance.
Debotton N; Zer H; Parnes M; Harush-Frenkel O; Kadouche J; Benita S
Eur J Pharm Biopharm; 2010 Feb; 74(2):148-56. PubMed ID: 19835957
[TBL] [Abstract][Full Text] [Related]
9. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles.
Lee AL; Wang Y; Cheng HY; Pervaiz S; Yang YY
Biomaterials; 2009 Feb; 30(5):919-27. PubMed ID: 19042015
[TBL] [Abstract][Full Text] [Related]
10. Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model.
Karra N; Nassar T; Ripin AN; Schwob O; Borlak J; Benita S
Small; 2013 Dec; 9(24):4221-36. PubMed ID: 23873835
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
[TBL] [Abstract][Full Text] [Related]
12. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
[TBL] [Abstract][Full Text] [Related]
13. Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine.
Hu N; Yin JF; Ji Z; Hong Y; Wu P; Bian B; Song Z; Li R; Liu Q; Wu F
Cell Physiol Biochem; 2017; 44(6):2158-2173. PubMed ID: 29241186
[TBL] [Abstract][Full Text] [Related]
14. Safety and proof-of-concept efficacy of inhaled drug loaded nano- and immunonanoparticles in a c-Raf transgenic lung cancer model.
Karra N; Nassar T; Laenger F; Benita S; Borlak J
Curr Cancer Drug Targets; 2013 Jan; 13(1):11-29. PubMed ID: 23030233
[TBL] [Abstract][Full Text] [Related]
15. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells.
Yu K; Zhao J; Zhang Z; Gao Y; Zhou Y; Teng L; Li Y
Int J Pharm; 2016 Jan; 497(1-2):78-87. PubMed ID: 26617314
[TBL] [Abstract][Full Text] [Related]
16. An effective treatment approach of DPP-IV inhibitor encapsulated polymeric nanoparticles conjugated with anti-CD-4 mAb for type 1 diabetes.
Thondawada M; Wadhwani AD; S Palanisamy D; Rathore HS; Gupta RC; Chintamaneni PK; Samanta MK; Dubala A; Varma S; Krishnamurthy PT; Gowthamarajan K
Drug Dev Ind Pharm; 2018 Jul; 44(7):1120-1129. PubMed ID: 29430979
[TBL] [Abstract][Full Text] [Related]
17. Targeted siRNA delivery by anti-HER2 antibody-modified nanoparticles of mPEG-chitosan diblock copolymer.
Wang Y; Liu P; Du J; Sun Y; Li F; Duan Y
J Biomater Sci Polym Ed; 2013; 24(10):1219-32. PubMed ID: 23713424
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
19. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
[TBL] [Abstract][Full Text] [Related]
20. Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.
Chuan X; Song Q; Lin J; Chen X; Zhang H; Dai W; He B; Wang X; Zhang Q
Mol Pharm; 2014 Oct; 11(10):3656-70. PubMed ID: 25208098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
